Core Viewpoint - Enwei Pharmaceutical has experienced a decline in stock price, with a cumulative drop of 5.48% over three consecutive days, currently trading at 33.97 CNY per share, with a market capitalization of 3.495 billion CNY [1] Company Overview - Enwei Pharmaceutical Co., Ltd. was established on May 19, 2005, and went public on September 21, 2022. The company is based in Chengdu, Sichuan Province, and focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, particularly in gynecology, pediatrics, and respiratory system medications [1] - The revenue composition of Enwei Pharmaceutical is as follows: gynecology products 46.21%, others 31.74%, cold medications 14.71%, pediatrics 6.90%, and other supplementary products 0.44% [1] Shareholder Insights - Among the top ten circulating shareholders of Enwei Pharmaceutical, the Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) reduced its holdings by 470,600 shares in the second quarter, now holding 529,400 shares, which represents 1.61% of the circulating shares. The estimated floating loss today is approximately 529,400 CNY, with a total floating loss of 1,042,900 CNY over the three-day decline [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund was established on December 25, 2014, with a current size of 2.074 billion CNY. Year-to-date returns are 21.65%, ranking 3,497 out of 8,180 in its category, while the one-year return is 44.14%, ranking 3,083 out of 7,967 [2]
恩威医药股价连续3天下跌累计跌幅5.48%，融通基金旗下1只基金持52.94万股，浮亏损失104.29万元